THERAPY DOSSIER · th-cdbeea31b43b

Pyr3 (ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29212271 ↗2017Reported benefit

Inhibition of astrocytic activity alleviates sequela in acute stages of intracerebral hemorrhage.

RatHaemorrhage/shockUnspecifiedSprague-DawleyMalen = 80 rats for the collagenase model (9 per group for MRI, 14…Intraventricular injection into the lateral ventricle ipsilateral to the lesionSuspended in 10% PEG-45 hydrogenated castor oil at 4 mmol/L…10 min after induction of intracerebral haemorrhage

Model: Intrastriatal collagenase-induced intracerebral haemorrhage, confirmed in a second model of autologous blood injection (30 microlitres of tail vein blood infused into the striatum over 10 min)

Pyr3 reduced haematoma size at 3, 12, 15 and 21 h, lowered T2-weighted and diffusion-weighted signal ratios, reduced blood-brain barrier leakage on Ktrans at 3 and 15 h, decreased perihaematomal GFAP-positive astrocyte accumulation and improved grip strength, rotarod performance and neurological de…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…